Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
69 hedge funds and large institutions have $174M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 13 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
1% less capital invested
Capital invested by funds: $176M → $174M (-$1.72M)
8% less funds holding
Funds holding: 75 → 69 (-6)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
+$11.9M |
| 2 |
6CM
683 Capital Management
New York
|
+$2.01M |
| 3 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$1M |
| 4 |
LC
Littlejohn & Co
Greenwich,
Connecticut
|
+$782K |
| 5 |
SC
Sculptor Capital
New York
|
+$723K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$4.35M |
| 2 |
HM
HealthCor Management
New York
|
-$3.49M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.48M |
| 4 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$1.78M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.77M |
PRDS Hedge Fund Activity: Q2 2021 in Review
69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q2 2021, worth a combined $174M — down 0.98% from $176M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PRDS and 7 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Arena Capital Advisors, adding an estimated $11.9M. The largest seller was Glazer Capital LLC, cutting an estimated $4.35M.
- 69 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q2 2021, down from 75 in Q1 2021.
- Funds reported $174M of Pardes Biosciences, Inc. Common Stock stock for Q2 2021, down 0.98% quarter-over-quarter.
- 7 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q2 2021 and 13 closed out, a net change of -6 holders.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q2 2021 was Arena Capital Advisors, an estimated $11.9M added.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q2 2021 was Glazer Capital LLC, an estimated $4.35M sold.
Based on aggregated 13F filings for Q2 2021.